These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 34548333)
1. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333 [TBL] [Abstract][Full Text] [Related]
2. Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Lin J; Liu H; Fukumoto T; Zundell J; Yan Q; Tang CA; Wu S; Zhou W; Guo D; Karakashev S; Hu CA; Sarma K; Kossenkov AV; Zhang R Nat Commun; 2021 Sep; 12(1):5321. PubMed ID: 34493732 [TBL] [Abstract][Full Text] [Related]
3. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768 [TBL] [Abstract][Full Text] [Related]
4. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609 [TBL] [Abstract][Full Text] [Related]
5. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852 [TBL] [Abstract][Full Text] [Related]
6. Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway. Namba T; Chu K; Kodama R; Byun S; Yoon KW; Hiraki M; Mandinova A; Lee SW Oncotarget; 2015 Aug; 6(24):19990-20001. PubMed ID: 26254280 [TBL] [Abstract][Full Text] [Related]
7. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer. Kim M; Lu F; Zhang Y Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437 [TBL] [Abstract][Full Text] [Related]
8. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Wu S; Fukumoto T; Lin J; Nacarelli T; Wang Y; Ong D; Liu H; Fatkhutdinov N; Zundell JA; Karakashev S; Zhou W; Schwartz LE; Tang HY; Drapkin R; Liu Q; Huntsman DG; Kossenkov AV; Speicher DW; Schug ZT; Van Dang C; Zhang R Nat Cancer; 2021 Feb; 2(2):189-200. PubMed ID: 34085048 [TBL] [Abstract][Full Text] [Related]
9. IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment. Harnoss JM; Le Thomas A; Reichelt M; Guttman O; Wu TD; Marsters SA; Shemorry A; Lawrence DA; Kan D; Segal E; Merchant M; Totpal K; Crocker LM; Mesh K; Dohse M; Solon M; Modrusan Z; Rudolph J; Koeppen H; Walter P; Ashkenazi A Cancer Res; 2020 Jun; 80(11):2368-2379. PubMed ID: 32265225 [TBL] [Abstract][Full Text] [Related]
10. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries. Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138 [TBL] [Abstract][Full Text] [Related]
12. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Wang FM; Galson DL; Roodman GD; Ouyang H Exp Hematol; 2011 Oct; 39(10):999-1006. PubMed ID: 21723843 [TBL] [Abstract][Full Text] [Related]
13. IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Song M; Sandoval TA; Chae CS; Chopra S; Tan C; Rutkowski MR; Raundhal M; Chaurio RA; Payne KK; Konrad C; Bettigole SE; Shin HR; Crowley MJP; Cerliani JP; Kossenkov AV; Motorykin I; Zhang S; Manfredi G; Zamarin D; Holcomb K; Rodriguez PC; Rabinovich GA; Conejo-Garcia JR; Glimcher LH; Cubillos-Ruiz JR Nature; 2018 Oct; 562(7727):423-428. PubMed ID: 30305738 [TBL] [Abstract][Full Text] [Related]
14. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1. Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687 [TBL] [Abstract][Full Text] [Related]
15. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703 [TBL] [Abstract][Full Text] [Related]
16. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Zhou W; Liu H; Yuan Z; Zundell J; Towers M; Lin J; Lombardi S; Nie H; Murphy B; Yang T; Wang C; Liao L; Goldman AR; Kannan T; Kossenkov AV; Drapkin R; Montaner LJ; Claiborne DT; Zhang N; Wu S; Zhang R Cancer Cell; 2023 Apr; 41(4):740-756.e10. PubMed ID: 36963401 [TBL] [Abstract][Full Text] [Related]
17. ER stress and distinct outputs of the IRE1α RNase control proliferation and senescence in response to oncogenic Ras. Blazanin N; Son J; Craig-Lucas AB; John CL; Breech KJ; Podolsky MA; Glick AB Proc Natl Acad Sci U S A; 2017 Sep; 114(37):9900-9905. PubMed ID: 28847931 [TBL] [Abstract][Full Text] [Related]
18. The IRE1α-XBP1 pathway positively regulates parathyroid hormone (PTH)/PTH-related peptide receptor expression and is involved in pth-induced osteoclastogenesis. Tohmonda T; Yoda M; Mizuochi H; Morioka H; Matsumoto M; Urano F; Toyama Y; Horiuchi K J Biol Chem; 2013 Jan; 288(3):1691-5. PubMed ID: 23235147 [TBL] [Abstract][Full Text] [Related]
19. Calreticulin promotes EMT in pancreatic cancer via mediating Ca Sheng W; Wang G; Tang J; Shi X; Cao R; Sun J; Lin YH; Jia C; Chen C; Zhou J; Dong M J Exp Clin Cancer Res; 2020 Oct; 39(1):209. PubMed ID: 33028359 [TBL] [Abstract][Full Text] [Related]
20. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Fukumoto T; Fatkhutdinov N; Zundell JA; Tcyganov EN; Nacarelli T; Karakashev S; Wu S; Liu Q; Gabrilovich DI; Zhang R Cancer Res; 2019 Nov; 79(21):5482-5489. PubMed ID: 31311810 [No Abstract] [Full Text] [Related] [Next] [New Search]